A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with abberant c-MET) in Colorectal Cancer Patients (MErCuRIC)

A DiCE Research Project

About MErCuRIC

MErCuRIC was a multicentre, investigator-driven phase Ib/II clinical trial to assess a novel therapeutic strategy (combined treatment of a MEK inhibitor MEK-162 with a MET inhibitor PF-02341066) to combat metastasis, improve survival and change current clinical practice for colorectal cancer (CRC) patients with RAS mutant (MT) and RAS wild-type (WT) (with aberrant c-MET) tumours. The project investigated using a novel treatment strategy targeting the biology of the disease and performed laboratory studies to identify CRC patient subgroups who might benefit most from the novel treatment strategy.

Find MErCuRIC promotional materials here.

Project Brochure

Our Partners

  • Queen’s University Belfast
  • Vall d’Hebron Institute of Oncology
  • University of Oxford
  • Universita Degli Studi di Torino
  • Universitair Ziekenhuis Antwerpen
  • Velindre National Health Service Trust
  • Royal College of Surgeons in Ireland
  • Paris Descartes University
  • Assistance Publique – Hopitaux de Paris
  • Agilent Technologies
  • Masarykova Univerzita
  • Pintail Limited
  • Belfast Health and Social Care Trust

Our Sponsors

MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The materials presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.